ChemotherapyPhase 3 trialInvestigational
Platinum-based chemotherapy
How it works
Damages DNA, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
Platinum-based chemotherapy has been shown to improve survival and reduce disease progression in men with metastatic prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Platinum in Treating Residual Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Surgery Benefits for Recurrent Ovarian Cancer Patients | Ovarian Cancer | observational | Complete macroscopic resection (R0) significantly improved survival across all surgeries, including secondary (36.6 vs. 15.3 months), tertiary (22.2 vs. 6.4 months), and quaternary (29.1 vs. 10.5 months). | Source → |
| Rare Lung Cancer Mutation Responds Poorly to Standard Treatment | Lung Cancer | observational | The median progression-free survival with first-line therapy was 7.4 months (95% CI: 3-12 months), and 9.8 months (95% CI: 3-27 months) for those receiving platinum-based chemotherapy in the first line. | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Platinum-based Chemotherapy in Ovarian Cancer Patients on PARP Inhibitors | Ovarian Cancer | observational | The objective response rate was 23.3%, and the disease control rate was 43.3%. | Source → |
| Predicting Response to Platinum-Based Chemotherapy in Ovarian Cancer | Ovarian Cancer | observational | The area under the curve (AUC) was 0.917 in the internal validation set, 0.877 in the external validation set using centre D, and 0.845 in the external validation set using centre E. | Source → |
| PARP Inhibitors Improve Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | Median overall survival was 82.0 months in the PARPi group vs 44.7 months in the control group. | Source → |
| New Biomarkers for Detecting Platinum Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | Both EV CFH and EV TMEM205 exhibited excellent diagnostic capability for PR as noted by receiver operating characteristic curves with area under the curve values of 0.95 and 0.84, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.